Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6217]

ASCO 2022: Nimotuzumab significantly improves overall survival for K-Ras wild-type advanced pancreatic cancer

ASCO 2022: Nimotuzumab significantly improves overall survival for K-Ras wild-type advanced pancreatic cancer

'Masked' cancer drug sneaks through body to deliver anti-tumour treatment with fewer side effects

'Masked' cancer drug sneaks through body to deliver anti-tumour treatment with fewer side effects

Age-related lung changes provide pathway for metastatic growth of dormant melanoma cancer cells

Age-related lung changes provide pathway for metastatic growth of dormant melanoma cancer cells

Cancer immunotherapy capable of modulating tumour immunophenotypes

Cancer immunotherapy capable of modulating tumour immunophenotypes

The paired perils of breast cancer and diabetes

The paired perils of breast cancer and diabetes

ASCO 2022: Follow-up data further support the superior efficacy of cabozantinib in patients with progressive differentiated thyroid cancer

ASCO 2022: Follow-up data further support the superior efficacy of cabozantinib in patients with progressive...

ECOG-ACRIN research highlights at ASCO 2022

ECOG-ACRIN research highlights at ASCO 2022

ASCO 2022: Targeting p53 pathway shows promise for patients with Merkel cell carcinoma

ASCO 2022: Targeting p53 pathway shows promise for patients with Merkel cell carcinoma

ASCO 2022: Novel immunotherapy combination improved survival in patients with metastatic melanoma

ASCO 2022: Novel immunotherapy combination improved survival in patients with metastatic melanoma

ASCO 2022: Study offers guidance for future trials of adjuvant therapy for patients with early HR+/HER2- breast cancer

ASCO 2022: Study offers guidance for future trials of adjuvant therapy for patients with early HR+/HER2- breast...

More from ecancer